Optimising ANCA-associated vasculitis management and infectious risks during the COVID-19 pandemic.

Guillevin, Loïc; Terrier, Benjamin

Guillevin, Loïc; Terrier, Benjamin.

Guillevin L; Department of Internal Medicine, Hôpital Cochin, Université Paris-Descartes, Paris, France. loic.guillevin@orange.fr.
Terrier B; Department of Internal Medicine, Hôpital Cochin, Université Paris-Descartes, Paris, France.

Clin Exp Rheumatol ; 40(4): 688-690, 2022 05.

Article in English | MEDLINE | ID: covidwho-1836719

Subject(s)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; COVID-19; Infections; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/epidemiology; Antibodies, Antineutrophil Cytoplasmic; Humans; Pandemics

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / COVID-19 / Infections Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Clin Exp Rheumatol Year: 2022 Document Type: Article Affiliation country: Clinexprheumatol

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google